Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R 763

Next Previous
X
Search
Drug Profile

R 763

Alternative Names: AS703569; R763

Latest Information Update: 01 Apr 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Merck Serono
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 28 Feb 2010 Merck Serono expects to wind down the various clinical trials for R 763 and plans to return the drug back to Rigel
  • 19 Nov 2009 Efficacy, adverse events & pharmacokinetic data from a phase I trial in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
  • 19 Nov 2009 Preclinical pharmacodynamics data in Haematological malignancies presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top